tratado_fibro_quistica

168 TRASTORNOS RELACIONADOS CON CFTR
Bibliografía
1. Rommens JM, Iannuzzi MC, Kerem B,
Drumm ML, Melmer G, Dean M, et al.
Identification of the cystic fibrosis gene:
chromosome walking and jumping. Science.
1989;245(4922):1059-65.
2. Riordan JR, Rommens JM, Kerem B, Alon N,
Rozmahel R, Grzelczak Z, et al. Identification
of the cystic fibrosis gene: cloning and
characterization of complementary DNA.
Science. 1989;245(4922):1066-73.
3. Kerem B, Rommens JM, Buchanan JA,
Markiewicz D, Cox TK, Chakravarti A, et al.
Identification of the cystic fibrosis gene: genetic
analysis. Science. 1989;245(4922):1073-80.
4. Castellani C, Cuppens H, Macek M Jr,
Cassiman JJ, Kerem E, Durie P, et al.
Consensus on the use and interpretation of
cystic fibrosis mutation analysis in clinical
practice. J Cyst Fibros. 2008;7(3):179-96.
5. Zielenski J. Genotype and phenotype in cystic
fibrosis. Respiration. 2000;67(2):117-33.
6. Rosenstein BJ, Cutting GR. The diagnosis of
cystic fibrosis: a consensus statement. Cystic
Fibrosis Foundation Consensus Panel. J Pediatr.
1998;132(4):589-95.
7. Chillon M, Casals T, Mercier B, Bassas L,
Lissens W, Silber S, et al. Mutations in
the cystic fibrosis gene in patients with
congenital absence of the vas deferens. N
Engl J Med. 1995;332(22):1475-80.
8. Cohn J A, Friedman K J, Noone PG, Knowles
MR, Silverman LM, Jowell PS. Relation between
mutations of the cystic fibrosis gene and
idiopathic pancreatitis. N Engl J Med.
1998;339(10):653-8.
9. Sharer N, Schwarz M, Malone G, Howarth
A, Painter J, Super M, et al. Mutations
of the cystic fibrosis gene in patients
with chronic pancreatitis. N Engl J Med.
1998;339(10):645-52.
10. Castellani C, Gomez Lira M, Frulloni L, Delmarco
A, Marzari M, Bonizzato A, et al. Analysis of
the entire coding region of the cystic fibrosis
transmembrane regulator gene in idiopathic
pancreatitis. Hum Mutat. 2001;18(2):166.
11. Ranieri E, Ryall RG, Lewis BD, Gerace RL,
Morris CP, Nelson PV, et al. Neonatal screening
for cystic fibrosis using immunoreactive
trypsinogen and direct gene analysis. BMJ.
1991;302(6787):1237-40.
12. Laroche D, Travert G. Abnormal frequency of
DF508 in neonatal transitory hypertrypsinaemia.
Lancet. 1991;337(8732):55.
13. Lecoq I, Brouard J, Laroche D, Férec C, Travert
G. Blood immunoreactive trypsinogen concentrations
are genetically determined in
healthy and cystic fibrosis newborns. Acta
Paediatr. 1999;88(3):338-41.
14. Castellani C, Picci L, Scarpa M, Dechecchi
MC, Zanolla L, Assael BM, et al. Cystic fibrosis
carriers have higher neonatal immunoreactive
trypsinogen values than non-carriers. Am J
Med Genet A. 2005;135(2):142-4.
15. Castellani C, Benetazzo MG, Tamanini
A, Begnini A, Mastella G, Pignatti PF.
Analysis of the entire coding region of the
cystic fibrosis transmembrane regulator
gene in neonatal hypertrypsinemia
with normal sweat test. J Med Genet.
2001;38(3):202-5.
16. Pignatti PF, Bombieri C, Marigo C, Benetazzo
M, Luisetti M. Increased incidence of cystic
fibrosis gene mutations in adults with
disseminated bronchiectasis. Hum Mol
Genet. 1995;4(4):635-9.
17. Wang X, Moylan B, Leopold DA, Kim J,
Rubenstein RC, Togias A, et al. Mutation
in the gene responsible for cystic fibrosis
and predisposition to chronic rhinosinusitis
in the general population. JAMA.
2000;284(14):1814-9.
18. Miller PW, Hamosh A, Macek M Jr,
Greenberger PA, MacLean J, Walden SM, et al.
Cystic fibrosis transmembrane conductance
regulator (CFTR) gene mutations in allergic
bronchopulmonary aspergillosis. Am J Hum
Genet. 1996;59(1):45-51.
19. Di Sant’Agnese PA, Darling RC, Perera GA,
Shea E. Abnormal electrolyte composition
of sweat in cystic fibrosis of the pancreas;
clinical significance and relationship to the
disease. Pediatrics. 1953;12(5):549-63.
20. Quinton PM. Chloride impermeability in cystic
fibrosis. Nature. 1983;301(5899):421-2.
21. Anderson MP, Gregory RJ, Thompson
S, Souza DW, Paul S, Mulligan RC, et al.
Demonstration that CFTR is a chloride
channel by alteration of its anion selectivity.
Science. 1991;253(5016):202-5.
22. Association of Clinical Biochemistry.
Guidelines for the performance of the sweat
test for the investigation of cystic fibrosis
in the UK, Report from the Multidisciplinary
Working Group, 2002. Available at http://
www.acb.org.uk.
23. National Committee for Clinical Laboratory
Standards (NCCLS). Sweat testing: sample
collection and quantitative analysis, Approved
guideline C34-A2. Wayne, PA: NCCLS, 2000.
24. Farrell PM, Koscik RE. Sweat chloride
concentrations in infants homozygous
or heterozygous for F508 cystic fibrosis.
Pediatrics. 1996;97(4):524-8.
25. Groman JD, Karczeski B, Sheridan M, Robinson
TE, Fallin MD, Cutting GR. Phenotypic and
genetic characterization of patients with
features of “nonclassic” forms of cystic
fibrosis. J Pediatr. 2005;146(5):675-80.
26. Farrell PM, Rosenstein BJ, White TB, Accurso
FJ, Castellani C, Cutting GR, et al. Cystic
Fibrosis Foundation. Guidelines for diagnosis
of cystic fibrosis in newborns through older
adults: Cystic Fibrosis Foundation consensus
report. J Pediatr. 2008;153(2):S4-S14.
27. Sosnay PR, Castellani C, Corey M, Dorfman
R, Zielenski J, Karchin R, et al. Evaluation
of the disease liability of CFTR variants.
Methods Mol Biol. 2011;742:355-72.
28. Knowles M, Gatzy J, Boucher R. Increase
bioelectric potential difference across
respiratory epithelia in cystic fibrosis. N Engl J
Med. 1981;305(25):1489-95.
29. Pradal U, Castellani C, Delmarco A, Mastella
G. Nasal potential difference in congenital
bilateral absence of the vas deferens. Am J
Respir Crit Care Med. 1998;158(3):896-
901.
30. Groman JD, Meyer ME, Wilmott RW, Zeitlin PL,
Cutting GR. Variant cystic fibrosis phenotypes
in the absence of CFTR mutations. N Engl J
Med. 2002;347(6):401-7.
31. Boyle MP. Nonclassic cystic fibrosis and
CFTR-related diseases. Curr Opin Pulm Med.
2003;9(6):498-503.
32. Bombieri C, Claustres M, De Boeck K,
Derichs N, Dodge J, Girodon E, et al.
Recommendations for the classification of
diseases as cftr-related disorders. J Cyst
Fibros. 2011;10 Suppl 2:S86-102.
33. Borowitz D, Parad RB, Sharp JK, Sabadosa
KA, Robinson KA, Rock MJ, et al. Cystic
Fibrosis Foundation practice guidelines for
the management of infants with cystic fibrosis
transmembrane conductance regulator-related
metabolic syndrome during the
first two years of life and beyond. J Pediatr.
2009;155(6 Suppl):S106-16.